ERBB2 and breast cancer: Detection of receptor overexpression via immunohistochemistry (IHC) and/or HER2 gene amplification using in situ hybridization (ISH) techniques in breast cancer tissue, including fluorescent ISH (FISH), determines patients’ eligibility to receive anti-HER2 therapies[5].